Compare Alphatec Holdings, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,930 Million (Small Cap)
NA (Loss Making)
NA
0.00%
11.69
-325.84%
54.97
Revenue and Profits:
Net Sales:
213 Million
(Quarterly Results - Dec 2025)
Net Profit:
-22 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-44.68%
0%
-44.68%
6 Months
-24.46%
0%
-24.46%
1 Year
9.53%
0%
9.53%
2 Years
-13.09%
0%
-13.09%
3 Years
-27.37%
0%
-27.37%
4 Years
6.78%
0%
6.78%
5 Years
-31.12%
0%
-31.12%
Alphatec Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
40.44%
EBIT Growth (5y)
-22.80%
EBIT to Interest (avg)
-10.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.44
Sales to Capital Employed (avg)
1.01
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
90.56%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
54.97
EV to EBIT
-31.83
EV to EBITDA
249.52
EV to Capital Employed
5.25
EV to Sales
3.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.50%
ROE (Latest)
-325.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 59 Schemes (23.36%)
Foreign Institutions
Held by 100 Foreign Institutions (14.45%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
212.90
176.80
20.42%
Operating Profit (PBDIT) excl Other Income
15.10
-0.10
15,200.00%
Interest
12.90
7.20
79.17%
Exceptional Items
-3.50
-2.90
-20.69%
Consolidate Net Profit
-21.70
-33.30
34.83%
Operating Profit Margin (Excl OI)
-25.20%
-118.30%
9.31%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 20.42% vs 28.12% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 34.83% vs 32.18% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
764.20
611.60
24.95%
Operating Profit (PBDIT) excl Other Income
24.60
-39.60
162.12%
Interest
45.90
24.90
84.34%
Exceptional Items
-41.10
-13.30
-209.02%
Consolidate Net Profit
-143.40
-162.10
11.54%
Operating Profit Margin (Excl OI)
-75.90%
-201.00%
12.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 24.95% vs 26.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.54% vs 13.13% in Dec 2024
About Alphatec Holdings, Inc. 
Alphatec Holdings, Inc.
Pharmaceuticals & Biotechnology
Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.
Company Coordinates 
Company Details
5818 El Camino Real , CARLSBAD CA : 92008
Registrar Details






